Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS5 | Q9UNA0 | 8/20 | 0.77 |
| ▸ | MMP13 | P45452 | 3/20 | 0.77 |
| ▸ | IDH1 | O75874 | 1/20 | 0.71 |
| ▸ | GSK3B | P49841 | 3/20 | 0.64 |
| ▸ | CNR1 | P21554 | 1/20 | 0.60 |
| ▸ | MMP3 | P08254 | 2/20 | 0.59 |
| ▸ | MGAM | O43451 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | SI | P14410 | 1/20 | 0.57 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.57 |
| ▸ | NAT1 | P18440 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7972188 | 1.00 | ADAMTS5 (0.77) | ADAMTS5MMP13IDH1GSK3BCNR1 | |
| SCHEMBL4048463 | 0.87 | MMP3 (0.73) | ADAMTS5MMP13MMP3 | |
| SCHEMBL4048467 | 0.87 | MMP3 (0.73) | ADAMTS5MMP13MMP3 | |
| SCHEMBL7958433 | 0.87 | MMP3 (0.73) | ADAMTS5MMP13MMP3 | |
| SCHEMBL1249080 | 0.87 | ADAMTS5 (1.00) | ADAMTS5MMP13IDH1GSK3BCNR1 | |
| SCHEMBL1249082 | 0.87 | ADAMTS5 (1.00) | ADAMTS5MMP13IDH1GSK3BCNR1 | |
| SCHEMBL12891797 | 0.87 | ADAMTS5 (1.00) | ADAMTS5MMP13IDH1GSK3BCNR1 | |
| SCHEMBL21538213 | 0.86 | ADAMTS5 (0.77) | ADAMTS5MMP13IDH1GSK3BCNR1 | |
| SCHEMBL7975071 | 0.85 | ADAMTS5 (0.70) | ADAMTS5MMP13IDH1GSK3BMMP3 | |
| SCHEMBL7975070 | 0.85 | ADAMTS5 (0.70) | ADAMTS5MMP13IDH1GSK3BMMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6251928-B1 | ADMINISTERING BENZYLIDENE RHODANINES WHICH ARE USEFUL AS AGENTS IN TREATING OR PREVENTING CONDITIONS ASSOCIATED WITH BETA-AMYLOID PEPTIDE IN A MAMMAL | ELI LILLY AND COMPANY | 2001-06-26 | — | — | US | disclosed |
| EP-0677517-A1 | Treatment of Alzheimer's disease employing inhibitors of cathepsin D | ELI LILLY AND COMPANY (US) | 1995-10-18 | — | — | EP | disclosed |